Leonard M. Azzarano

535 total citations
11 papers, 289 citations indexed

About

Leonard M. Azzarano is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Leonard M. Azzarano has authored 11 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Leonard M. Azzarano's work include Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Analytical Chemistry and Chromatography (2 papers). Leonard M. Azzarano is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Analytical Chemistry and Chromatography (2 papers). Leonard M. Azzarano collaborates with scholars based in United States, United Kingdom and Canada. Leonard M. Azzarano's co-authors include Keith W. Ward, Brian R. Smith, Keith W. Ward, Brian R. Smith, Jonathan Kehler, Jeanelle McSurdy-Freed, Joel W. Proksch, Kevin L. Salyers, Albert S. Kearney and Katie Ward and has published in prestigious journals such as Scientific Reports, Journal of Pharmacology and Experimental Therapeutics and International Journal of Pharmaceutics.

In The Last Decade

Leonard M. Azzarano

10 papers receiving 277 citations

Peers

Countries citing papers authored by Leonard M. Azzarano

Since Specialization

Citations

This map shows the geographic impact of Leonard M. Azzarano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard M. Azzarano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard M. Azzarano more than expected).

Fields of papers citing papers by Leonard M. Azzarano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard M. Azzarano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard M. Azzarano. The network helps show where Leonard M. Azzarano may publish in the future.

Co-authorship network of co-authors of Leonard M. Azzarano

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard M. Azzarano. A scholar is included among the top collaborators of Leonard M. Azzarano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard M. Azzarano. Leonard M. Azzarano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Parenteral platforms for tunable, long-acting administration of a highly hydrophobic antiretroviral drug 2024 ·Scientific Reports ·(unknown), Marc M. Baum, Manjula Gunawardana, John A. Moss, (unknown), (unknown), Rob Fanter, (unknown), (unknown), Leonard M. Azzarano, (unknown), Beat M. Jucker, Brian A. Johns, (unknown), (unknown)	0
2	Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Marlys Hammond, David G. Washburn, Tram H. Hoang, (unknown), James S. Frazee, Hiroko Nakamura, Jaclyn R. Patterson, Walter Trizna, Charlene Wu, Leonard M. Azzarano, Rakesh Nagilla, (unknown), (unknown), Martha S. Head, Baoguang Zhao, Angela Smallwood, Kendra E. Hightower, Nicholas J. Laping, Christine G. Schnackenberg, Scott K. Thompson	37
3	Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Michael R. Palovich, Katherine L. Widdowson, (unknown), Miriam Burman, James J. Foley, Dulcie B. Schmidt, Henry M. Sarau, Martin Rogers, Kevin L. Salyers, Peter D. Gorycki, Theresa J. Roethke, (unknown), Leonard M. Azzarano, Keith W. Ward, Jakob Busch‐Petersen	32
4	Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Keith W. Ward, Leonard M. Azzarano	53
5	Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. II. Studies implicating transporter-mediated intestinal secretion 2004 ·Xenobiotica ·Keith W. Ward, (unknown), Jonathan Kehler, Leonard M. Azzarano, Brian R. Smith	23
6	DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY 2004 ·Drug Metabolism and Disposition ·Keith W. Ward, (unknown), (unknown), (unknown), Leonard M. Azzarano, Jonathan Kehler, Jeanelle McSurdy-Freed, Joel W. Proksch, Brian R. Smith	37
7	Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations 2004 ·Xenobiotica ·Katie Ward, Leonard M. Azzarano, (unknown), Brian R. Smith	19
8	Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens 2002 ·International Journal of Pharmaceutics ·(unknown), Albert S. Kearney, (unknown), Brian R. Smith, Leonard M. Azzarano	30
9	SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics 2002 ·Xenobiotica ·Katie Ward, Joel W. Proksch, Kevin L. Salyers, Leonard M. Azzarano, (unknown), Theresa J. Roethke, Jeanelle McSurdy-Freed, Mark A. Levy, Brian R. Smith	11
10	SB-239063, a Potent and Selective Inhibitor of P38 Map Kinase: Preclinical Pharmacokinetics and Species-Specific Reversible Isomerization 2001 ·Pharmaceutical Research ·Keith W. Ward, Joel W. Proksch, Leonard M. Azzarano, Kevin L. Salyers, Jeanelle McSurdy-Freed, (unknown), Mark A. Levy, Brian R. Smith	14
11	Preclinical Pharmacokinetics and Interspecies Scaling of a Novel Vitronectin Receptor Antagonist 1999 ·Drug Metabolism and Disposition ·Keith W. Ward, Leonard M. Azzarano, William E. Bondinell, Russell D. Cousins, William F. Huffman, Dalia R. Jakas, Richard M. Keenan, Thomas W. Ku, D. Lundberg, William H. Miller, (unknown), K. A. NEWLANDER, (unknown), Theresa J. Roethke, Kevin L. Salyers, (unknown), (unknown), Brian R. Smith	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact